PR Newswire·May 28, 2026, 9:00 AM ET

Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset

Erasca Inc. (NASDAQ: ERAS) shares fell $9.25 (-48%) on April 28, 2026, after competitor Revolution Medicines challenged the intellectual property claims surrounding Erasca's lead candidate ERAS-0015.
Hagens Berman has launched an investigation to determine if Erasca misled investors regarding the viability & protection of its ERAS-0015 intellectual property.
The legal challenge, filed by Revolution Medicines, alleges trade secret misappropriation, patent infringement, & improper preclinical data comparisons between ERAS-0015 & RevMed's RMC-6236.
Erasca had previously assured investors on March 12, 2026, that it held an issued US patent, a pending US application, an issued foreign patent, & thirteen pending foreign applications for its technology.
The sudden market reaction erased over $2.8 billion in Erasca's market capitalization in a single day.
Hagens Berman urges affected investors to contact the firm to discuss their rights & potential recovery options.
Whistleblowers with non-public information are encouraged to report details to assist the investigation or utilize the SEC Whistleblower program for potential rewards.